Clinical Trial Update: Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing tailored antiplatelet therapy to the recommended prasugrel dose in Acute Coronary Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• PRASUGREL (prasugrel)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Acute Coronary Syndrome | Phase 4 | Status: COMPLETED